Wordt geladen...
Belimumab for systemic lupus erythematosus
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...
Bewaard in:
| Gepubliceerd in: | Cochrane Database Syst Rev |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Ltd
2021
|
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/ https://ncbi.nlm.nih.gov/pubmed/33631841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|